Home » Stocks » CYDY » Company

CytoDyn, Inc. (CYDY)

Stock Price: $1.60 USD -0.02 (-1.23%)
Updated Jul 27, 2021 3:59 PM EDT - Market closed
CytoDyn, Inc.
Industry Biotechnology
Sector Healthcare
Employees 19

Contact Details

Address:1111 Main Street
Vancouver, WA 98660
United States
Phone 360 980 8524

Stock Information

Ticker Symbol CYDY
Exchange OTCMKTS
Fiscal Year June - May
Reporting Currency US Dollars
CIK Code 0001175680
CUSIP Number 23283M101
ISIN Number US23283M1018
Employer ID 83-1887078

Company Description

CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.

Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19).

It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.

The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient.

The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Key Executives

NamePosition
Dr. Scott A. KellyChairman, Chief Medical Officer and Head of Business Development
Dr. Nader Z. PourhassanChief Executive Officer, President and Director
Dr. Nitya G. RayChief Technology Officer and Head of Process Sciences, Manufacturing and Supply Chain
Michael D. Mulholland CPA, CPASenior Vice President of Finance
Antonio MigliareseChief Financial Officer and Treasurer
Dr. Christopher P. Recknor M.D.Chief Operating Officer and Head of Clinical Development
Arian Colachis J.D.Senior Vice President, General Counsel and Corporate Secretary
Dr. Brendan P. RaeSenior Vice President of Business Development
George BitarHead of Quality and Executive Director
Dr. Kush DhodySenior Vice President of Clinical Operations